About the Liver Cancer Clinical Program

Mount Sinai’s Liver Cancer Clinical Program is committed to providing patients with the most advanced care for a range of conditions, including hepatocellular carcinoma (HCC), cholangiocarcinoma (bile duct cancer), gallbladder cancer, and metastatic liver tumors. Under the leadership of Director Myron Schwartz, MD, the new surgical techniques and treatment protocols pioneered by our Program have placed Mount Sinai at the forefront of excellence in care for patients with liver cancer. We have designed screening and surveillance programs for patients in our community at risk for developing liver cancer, and as a result we are able to offer potentially curative surgery to more than half of the liver cancer patients in our care.

As a result of our Program’s wealth of experience in liver transplantation and liver surgery, we have also developed innovative approaches to a variety of benign conditions, such as congenital abnormalities, bile duct injuries, and non-cancerous tumors.

Our Multidisciplinary Care

The Liver Cancer Program team comprises specialists such as hepatologists, surgeons, oncologists, pathologists, and radiologists, who work together to tailor the optimal treatment plan for each patient. The care we provide includes a number of treatments including:

  • Surgery (liver resection and liver transplantation)
  • Interventional radiology (ablation, radioembolization, stereotactic body radiation therapy)
  • Chemoembolization
  • Medical (systemic) treatment

Liver Cancer Research

Under the leadership of Josep Llovet, MD, the Liver Cancer Research Program is committed to advancing our understanding of the molecular mechanisms underlying chronic liver disease in order to enhance our ability to detect, treat, and cure HCC. The Research Program is leading the field in identifying new targets for tumor treatment, making discoveries in the laboratory that are leading to trials of new drugs that promise to help liver cancer patients worldwide.